165 related articles for article (PubMed ID: 38107071)
1. Ribociclib-induced liver injury: a case report.
Schaeffer S; Lutz C; Dobbie M; Terracciano LM; Matter M; Vosbeck J; Heim MH; Bernsmeier C
Front Oncol; 2023; 13():1256783. PubMed ID: 38107071
[TBL] [Abstract][Full Text] [Related]
2. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.
Topcu A; Yasin AI; Shbair AT; Besiroglu M; Simsek M; Sucuoglu Z; Yurtsever I; Gucin Z; Seker M; Turk HM
J Oncol Pharm Pract; 2022 Jan; 28(1):242-246. PubMed ID: 34162247
[TBL] [Abstract][Full Text] [Related]
3. An Update on Drug-induced Liver Injury.
Devarbhavi H
J Clin Exp Hepatol; 2012 Sep; 2(3):247-59. PubMed ID: 25755441
[TBL] [Abstract][Full Text] [Related]
4. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.
Edessa D; Sisay M
Breast Cancer (Dove Med Press); 2017; 9():567-579. PubMed ID: 29263697
[TBL] [Abstract][Full Text] [Related]
5. Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab.
Bayram D; Aktürk Esen S; Uçar G; Köş FT
J Oncol Pharm Pract; 2023 Sep; 29(6):1494-1497. PubMed ID: 37170613
[TBL] [Abstract][Full Text] [Related]
6. Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature.
Abeles RD; Foxton M; Khan S; Goldin R; Smith B; Thursz MR; Verma S
BMJ Open Gastroenterol; 2020 Nov; 7(1):. PubMed ID: 33214235
[TBL] [Abstract][Full Text] [Related]
7. Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.
Studentova H; Volakova J; Spisarova M; Zemankova A; Aiglova K; Szotkowski T; Melichar B
BMC Gastroenterol; 2022 Feb; 22(1):49. PubMed ID: 35123392
[TBL] [Abstract][Full Text] [Related]
8. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
9. The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.
Devarbhavi H; Joseph T; Sunil Kumar N; Rathi C; Thomas V; Prasad Singh S; Sawant P; Goel A; Eapen CE; Rai P; Arora A; Leelakrishnan V; Gopalakrishnan G; Vardhan Reddy V; Singh R; Goswami B; Venkataraman J; Balaraju G; Patil M; Patel R; Taneja S; Koshy A; Nagaraja Rao P; Kumar Sarin S; Rathi P; Dhiman R; Duseja AK; Vargese J; Kumar Jain A; Wadhawan M; Ranjan P; Karanth D; Ganesh P; Nijhawan S; Krishna Dhali G; Adarsh CK; Jhaveri A; Nagral A; Rao P; Shalimar
J Clin Exp Hepatol; 2021; 11(3):288-298. PubMed ID: 33994711
[TBL] [Abstract][Full Text] [Related]
10. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
Decker T; Lüdtke-Heckenkamp K; Melnichuk L; Hirmas N; Lübbe K; Zahn MO; Schmidt M; Denkert C; Lorenz R; Müller V; Zahm DM; Mundhenke C; Bauer S; Thill M; Seropian P; Filmann N; Loibl S
Breast; 2023 Dec; 72():103575. PubMed ID: 37690320
[TBL] [Abstract][Full Text] [Related]
11. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
13. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
14. Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations.
Teschke R
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047633
[TBL] [Abstract][Full Text] [Related]
15. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM.
Kobayashi T; Iwaki M; Nogami A; Yoneda M
J Clin Transl Hepatol; 2023 Oct; 11(5):1239-1245. PubMed ID: 37577239
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib-induced visual hallucination in a patient with metastatic breast cancer.
Kapagan T; Bulut N; Demirer S; Erdem GU
J Oncol Pharm Pract; 2023 Sep; 29(6):1529-1532. PubMed ID: 37306182
[TBL] [Abstract][Full Text] [Related]
18. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis.
Swanson LA; Kassab I; Tsung I; Schneider BJ; Fontana RJ
Front Oncol; 2022; 12():984940. PubMed ID: 36353563
[TBL] [Abstract][Full Text] [Related]
19. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
